N4 Pharma, the Derbyshire-based, AIM-listed biotech developing Nuvec, its gene delivery system to enable advanced therapies for cancer and other diseases, has appointed Edward Wardle as a non-executive director of the company.
Edward is joining the board as a representative of Northern Standard Limited, which is the company’s largest shareholder. Edward brings board-level experience of strategy, corporate governance and business development.
Having founded and led multiple businesses, he is currently an investment adviser with Tracarta Limited and Northern Standard Limited, focusing on critical industries and cutting-edge technologies, as well as a senior business development executive at Ironveld plc.
He joined the board of AIM-listed TheraCryf plc, the clinical stage drug development company focusing on neuropsychiatry and oncology, as a non-executive director in May 2025.
Nigel Theobald, chief executive officer of N4 Pharma, said: “We are delighted to welcome Ed to the Board of N4 Pharma, representing our largest shareholder.
“His experience in strategy, corporate governance, business development, and his background in innovative technologies will be invaluable as N4 Pharma develops its Nuvec® platform and continues to build out its data packages to secure licensing opportunities.”
Edward Wardle said: “Northern Standard sees a future where N4 Pharma’s Nuvec® platform shifts the paradigm of drug delivery by enabling the evolution of advanced RNA therapies; where time-consuming, in-clinic injections become something as small as a pill.
“We believe N4 Pharma has the technology, IP, and world-class team necessary to deliver this future, and are honoured to support them as they do.”
